Download Files:
Products Details
Product Description
– Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3].
Web ID
– HY-18263A
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H17Cl2FN4O4S
References
– [1]Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20(1):52-9.|[2]Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24(7):949-56.|[3]Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72(2):282-93.
CAS Number
– 688763-64-6
Molecular Weight
– 463.31
SMILES
– O=C(NC1=CC=C(Cl)C(S(=O)(N2CCNCC2)=O)=C1O)NC3=CC=CC(F)=C3Cl
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– CXCR;Interleukin Related
Isoform
– CXCR2;IL-8
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
